Trial Profile
An Observational Study of Cardiac Events in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- Acronyms OHERA
- Sponsors Roche
- 12 Sep 2017 Final analysis results (n=3733, data collected for up to 5 years or until death, loss to follow-up or consent withdrawal), presented at the 42nd European Society for Medical Oncology Congress.
- 04 Nov 2016 Status changed from active, no longer recruiting to completed.
- 26 Jan 2015 Planned End Date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov.